|
|
ADCs are formed by conjugating monoclonal antibodies (mAb) and small-molecule drugs through linkers. The specificity of mAb to tumor cells allows small-molecule drugs to target tumor tissues, effectively reducing the high toxicity of traditional small-molecule drugs and improving overall treatment efficiency. Learn more about <a href="https://adc.bocsci.com/services/adc-manufacture.html">ADC manufacturing</a>.